Author(s): Zhang BB, Moller DE, Zhang BB, Moller DE
Abstract Share this page
Abstract Type 2 diabetes is a chronic metabolic derangement that results from defects in both insulin action and secretion. New thiazolidinedione insulin sensitizers have been recently launched. New approaches with mechanisms different from current therapies are being explored, including novel ligands of peroxisome proliferator-activated receptor, glucagon receptor antagonists, dipeptidyl peptidase IV inhibitors, and insulin receptor activators.
This article was published in Curr Opin Chem Biol
and referenced in Alternative & Integrative Medicine